CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée
View original source (Euronext)
Earlier from Crossject Sa
- CROSSJECT and BARDA align ZEPIZURE®’s Pediatric development plan with FDA including funding through 2030
- CROSSJECT: Information relative au nombre total de droits de vote et d'actions composant le capital social
- CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million
- CROSSJECT appoints Lionel Seltz as Chief Financial Officer